-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Hennion & Walsh Asset Management Inc. Acquires 33,325 Shares of BeyondSpring Inc. (NASDAQ:BYSI)
Hennion & Walsh Asset Management Inc. Acquires 33,325 Shares of BeyondSpring Inc. (NASDAQ:BYSI)
Hennion & Walsh Asset Management Inc. increased its holdings in shares of BeyondSpring Inc. (NASDAQ:BYSI – Get Rating) by 65.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,408 shares of the company's stock after buying an additional 33,325 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in BeyondSpring were worth $186,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Fox Run Management L.L.C. bought a new stake in shares of BeyondSpring during the 4th quarter worth $56,000. GSA Capital Partners LLP acquired a new position in BeyondSpring in the 4th quarter worth about $83,000. Alps Advisors Inc. acquired a new position in BeyondSpring in the 4th quarter worth about $205,000. Finally, BNP Paribas Arbitrage SA increased its holdings in BeyondSpring by 2,749.1% in the 4th quarter. BNP Paribas Arbitrage SA now owns 109,890 shares of the company's stock worth $498,000 after purchasing an additional 106,033 shares in the last quarter. 18.89% of the stock is currently owned by institutional investors.
Get BeyondSpring alerts:BeyondSpring Stock Up 1.3 %
Shares of BYSI opened at $1.60 on Friday. BeyondSpring Inc. has a 12-month low of $1.13 and a 12-month high of $33.00. The business has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $2.28. The stock has a market cap of $62.29 million, a PE ratio of -0.98 and a beta of 1.10.
BeyondSpring (NASDAQ:BYSI – Get Rating) last issued its earnings results on Thursday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. BeyondSpring had a negative return on equity of 144.52% and a negative net margin of 4,750.48%. The firm had revenue of $0.34 million during the quarter. On average, equities research analysts expect that BeyondSpring Inc. will post -0.95 EPS for the current year.BeyondSpring Profile
(Get Rating)
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on BeyondSpring (BYSI)
- MarketBeat: Week in Review 7/11 – 7/15
- Is Coupang's Stock On The Verge Of A Turnaround?
- Should You Have These Two Banks In Your Portfolio?
- Verint Systems Stock is a Customer Engagement Play
- Why Shopify Stock Split...And is as Shoppable as Ever
Want to see what other hedge funds are holding BYSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeyondSpring Inc. (NASDAQ:BYSI – Get Rating).
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
Hennion & Walsh Asset Management Inc. increased its holdings in shares of BeyondSpring Inc. (NASDAQ:BYSI – Get Rating) by 65.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,408 shares of the company's stock after buying an additional 33,325 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in BeyondSpring were worth $186,000 at the end of the most recent reporting period.
據納斯達克在提交給美國證券交易委員會的最新文件中稱，該公司今年第一季度增持了65.2%的美團股票。該基金在本季度額外購買了33,325股後，持有84,408股該公司股票。截至上一次報告所述期間末，亨尼翁-沃爾什資產管理公司持有的萬春醫藥股份價值18.6萬美元。
Other institutional investors and hedge funds have also modified their holdings of the company. Fox Run Management L.L.C. bought a new stake in shares of BeyondSpring during the 4th quarter worth $56,000. GSA Capital Partners LLP acquired a new position in BeyondSpring in the 4th quarter worth about $83,000. Alps Advisors Inc. acquired a new position in BeyondSpring in the 4th quarter worth about $205,000. Finally, BNP Paribas Arbitrage SA increased its holdings in BeyondSpring by 2,749.1% in the 4th quarter. BNP Paribas Arbitrage SA now owns 109,890 shares of the company's stock worth $498,000 after purchasing an additional 106,033 shares in the last quarter. 18.89% of the stock is currently owned by institutional investors.
其他機構投資者和對衝基金也調整了對該公司的持股。福克斯奔跑管理有限公司在第四季度購買了價值56,000美元的萬春醫藥新股。GSA Capital Partners LLP在第四季度收購了萬春醫藥的一個新頭寸，價值約83,000美元。阿爾卑斯顧問公司(Alps Advisors Inc.)在第四季度收購了萬春醫藥的一個新頭寸，價值約20.5萬美元。最後，法國巴黎銀行套利公司在第四季度增持了2,749.1%的萬春醫藥。法國巴黎銀行套利公司現在持有109,890股該公司股票，價值49.8萬美元，上個季度又購買了106,033股。目前該公司18.89%的股份由機構投資者持有。
BeyondSpring Stock Up 1.3 %
萬春醫藥股價上漲1.3%
Shares of BYSI opened at $1.60 on Friday. BeyondSpring Inc. has a 12-month low of $1.13 and a 12-month high of $33.00. The business has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $2.28. The stock has a market cap of $62.29 million, a PE ratio of -0.98 and a beta of 1.10.
上週五，比亞迪的股價開盤報1.60美元。萬春醫藥股價跌至1.13美元的12個月低點和33.00美元的12個月高位。該業務的50日簡單移動均線切入位在1.47美元，200日簡單移動均線切入位在2.28美元。該股市值為6,229萬美元，市盈率為-0.98，貝塔係數為1.10。
BeyondSpring Profile
萬春醫藥簡介
(Get Rating)
(獲取評級)
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.
萬春醫藥是一家臨牀期生物製藥公司，與其子公司一起專注於癌症療法的開發。該公司的主要資產是普利布林，這是一種選擇性免疫調節微管結合劑，已經完成了預防化療引起的中性粒細胞減少症和治療晚期非小細胞肺癌的第三階段臨牀試驗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on BeyondSpring (BYSI)
- MarketBeat: Week in Review 7/11 – 7/15
- Is Coupang's Stock On The Verge Of A Turnaround?
- Should You Have These Two Banks In Your Portfolio?
- Verint Systems Stock is a Customer Engagement Play
- Why Shopify Stock Split...And is as Shoppable as Ever
- 在新浪萬春醫藥上免費獲取斯托克新聞網的研究報告
- MarketBeat：回顧一週7/11-7/15
- Coupang的股票即將翻身嗎？
- 你的投資組合中應該有這兩家銀行嗎？
- Verint Systems Stock是一場客户互動活動
- 為什麼Shopify股票拆分...並一如既往地適合購物
Want to see what other hedge funds are holding BYSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeyondSpring Inc. (NASDAQ:BYSI – Get Rating).
想看看其他對衝基金持有BYSI的哪些股份嗎？訪問HoldingsChannel.com獲取萬春醫藥的最新13F備案文件和內幕交易。(納斯達克代碼：BYSI-GET Rating)
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
接受萬春醫藥日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對萬春醫藥及相關公司評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧